The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improvements as early as Week 4, sustained through 52 weeks, with a good safety profile. This is the first registrational study targeting FcRn in autoimmune myositis, addressing a critical unmet need as few treatment options exist. Results will be presented as a late-breaking oral presentation at the American College of Rheumatology (ACR) Convergence 2026 in November.
The argenx Phase 3 ALKIVIA trial results in autoimmune myositis provide context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Oct 19, 2026 18:43 WIB: out of 150 priced US health stocks, 68 rose and 54 fell. Notable movers include HRTX at USD 0.37 with a 2.49% increase, RVMD at USD 181.96 up 2.25%, and ARWR at USD 56.94 rising 1.86%.
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...
EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...
Agility Robotics announced that Mark Vale, former UPS president and current CEO of Transportation Insight, will join its board and chair the audit committee after its merger with Churchill Capital Corp XI. Vale's extensive experience in global logist...
